



1 Fw

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q82704

Hideki ENDOH, et al.

Appln. No.: 10/502,279

Group Art Unit: 1639

Confirmation No.: 2122

Examiner: Amber D. Steele

Filed: July 23, 2004

For: METHOD FOR SCREENING A DRUG AMELIORATING INSULIN RESISTANCE

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following corrections:

Title

~~Method for screening drug for improving insulin resistance~~

Method for screening a drug ameliorating insulin resistance

Power of Attorney

~~Mark Boland 32197~~


The patent practitioners associated with the Customer Number 23373

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT
U.S. Appln. No.: 10/502,279

Atty. Docket No.: Q82704

Verification for the requested corrections is indicated on the Declaration and Power of Attorney filed on July 23, 2004 and Assignment filed on October 26, 2004.

Respectfully submitted,

A handwritten signature in cursive script, reading "Susan J. Mack", written over a horizontal line.

Susan J. Mack
Registration No. 30,951


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 18, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,279	07/23/2004	1646	1540	Q82704	8	19	6

CONFIRMATION NO. 2122

23373
 SUGHRUE MION, PLLC
 2100 PENNSYLVANIA AVENUE, N.W.
 SUITE 800
 WASHINGTON, DC 20037

FILING RECEIPT



OC000000014858591

Date Mailed: 01/04/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Hideki Endoh, Ibaraki, JAPAN;
 Ryosuke Nakano, Ibaraki, JAPAN;
 Eiji Kurosaki, Ibaraki, JAPAN;
 Miyuki Kato, Ibaraki, JAPAN;
 Hiroyuki Yokota, Ibaraki, JAPAN;
 Kazunori Inabe, Ibaraki, JAPAN;

Power of Attorney:

~~Mark Boland 32497~~

*The patent practitioners associated with Customer
 Number 23373*

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/00546 01/22/2003

Foreign Applications

JAPAN 2002-13721 01/23/2002
 JAPAN 2002-257703 09/03/2002

Projected Publication Date: 04/07/2005

Non-Publication Request: No



Early Publication Request: No

Title *Method for screening a drug ameliorating insulin resistance*
~~Method for screening drug for improving insulin resistance~~

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Method for screening a drug ameliorating insulin resistance

the application of which

☐ is attached hereto

OR

January 22,

☒ was filed on 2003 as United States Application Number or PCT International Application Number PCT/JP03/00546 (Confirmation No. _____), and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Claimed	
			Yes	No
P. 2002-013721	Japan	January 23, 2002	<input checked="" type="checkbox"/>	<input type="checkbox"/>
P. 2002-257703	Japan	September 03, 2002	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status

I hereby appoint all attorneys of **SUGHRUE MION, PLLC** who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.




23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:			
Given Name (first and middle [if any]) Hideki		Family Name or Surname ENDOH	
Inventor's Signature <i>Hideki Endoh</i>		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan
NAME OF SECOND INVENTOR:			
Given Name (first and middle [if any]) Ryosuke		Family Name or Surname NAKANO	
Inventor's Signature <i>Ryosuke Nakano</i>		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan
NAME OF THIRD INVENTOR:			
Given Name (first and middle [if any]) Ei-ji		Family Name or Surname KUROSAKI	
Inventor's Signature <i>Ei-ji Kuroski</i>		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan
NAME OF FOURTH INVENTOR:			
Given Name (first and middle [if any]) Miyuki		Family Name or Surname KATO	
Inventor's Signature <i>Miyuki Kato</i>		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan
NAME OF FIFTH INVENTOR:			
Given Name (first and middle [if any]) Hiroyuki		Family Name or Surname YOKOTA	
Inventor's Signature <i>Hiroyuki Yokota</i>		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan

NAME OF SIXTH INVENTOR:			
Given Name (first and middle [if any]) Kazunori		Family Name or Surname INABE	
Inventor's Signature 		Date July 20, 2004	
Residence: City Tsukuba-shi	State Ibaraki	Country Japan	Citizenship Japan
Mailing Address: c/o Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka,			
City Tsukuba-shi	State Ibaraki	Zip 305-8585	Country Japan
NAME OF SEVENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF EIGHTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF NINTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country
NAME OF TENTH INVENTOR:			
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	Zip	Country

ASSIGNMENT

Whereas, I/we Hideki ENDOH, Ryosuke NAKANO, Eiji KUROSAKI, Miyuki KATO, Hiroyuki YOKOTA and Kazunori INABE, all of Ibaraki, Japan

hereinafter called assignor(s), have invented certain improvements in

Method for screening a drug ameliorating insulin resistance and executed an application for Letters Patent of the United States of America therefor on

July 20, 2004

~~2004~~ and

Whereas, YAMANOUCI PHARMACEUTICAL CO., LTD.
3-11, Nihonbashi-Honcho 2-chome,
Chuo-ku, Tokyo 103-8411 Japan

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director - U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application number 10/502,279, filed July 23, 2004) the filing date and application number of said application when known.

Date: August 31, 2004

s/ Hideki Endoh.
Hideki ENDOH

Date: August 31, 2004

s/ Ryosuke Nakano.
Ryosuke NAKANO

Date: August 31, 2004

s/ Eiji Kuroaki
Eiji KUROSAKI

Date: August 31, 2004

s/ Miyuki Kato
Miyuki KATO

Date: August 31, 2004

s/ Hiroyuki Yokota
Hiroyuki YOKOTA

Date: August 31, 2004

s/ Kazunori Inabe
Kazunori INABE

FILED
OCT 26 2004